Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.
Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- Check5 days agoChange DetectedThe website has been updated from version v2.10.2 to v2.10.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe website has added new content, while the FDA Safety Alerts and Recalls section has been removed.SummaryDifference0.3%
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe website has been updated from version 2.10.0 to 2.10.2, indicating new features or improvements.SummaryDifference0.1%
- Check33 days agoNo Change Detected
- Check47 days agoChange DetectedThe study has expanded to include 29 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.5%
- Check49 days agoChange DetectedA new Investigator Inquiry form has been added to the website.SummaryDifference0.2%
- Check55 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.